Trials / Withdrawn
WithdrawnNCT02129322
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1
Effect of Adjuvant Therapy by Sorafenib, Oxaliplatin and S-1o Prevent the Tumor Recurrence for Hepatocellular Carcinoma After Liver Transplantation: A Randomized Controlled Study
- Status
- Withdrawn
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Zhejiang University · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The study is designed to investigate the effect of adjuvant therapy by Sorafenib, Oxaliplatin and S-1 to prevent the tumor recurrence for hepatocellular carcinoma after liver transplantation
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib | |
| DRUG | S-1 | |
| DRUG | Oxaliplatin |
Timeline
- Start date
- 2015-07-01
- Primary completion
- 2017-06-01
- Completion
- 2019-12-01
- First posted
- 2014-05-02
- Last updated
- 2021-02-15
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT02129322. Inclusion in this directory is not an endorsement.